Drug intelligence / Profile preview

FRECLOVIR

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

FRECLOVIR is a generic antiviral medication manufactured by the Vietnamese pharmaceutical company Fremed. It contains acyclovir, a synthetic purine nucleoside analogue that exhibits inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), as well as varicella-zoster virus (VZV). Acyclovir functions as a prodrug; it is selectively converted into acyclovir monophosphate by viral thymidine kinase, and subsequently into acyclovir triphosphate by host cell kinases. Acyclovir triphosphate acts as a competitive inhibitor of viral DNA polymerase and, more importantly, is incorporated into the growing viral DNA chain, where it acts as a potent chain terminator due to the lack of a 3'-hydroxyl group. This mechanism effectively halts viral replication. FRECLOVIR is commercially available in 200 mg and 400 mg tablet formulations for the treatment of various herpetic infections.

Brand names
FRECLOVIRFRECLOVIR 200FRECLOVIR200FRECLOVIR-200FRECLOVIR 400FRECLOVIR400FRECLOVIR-400
Other names
acyclovir
02

Targets

DNA polymerase family

Beyond the preview

Go deeper on FRECLOVIR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FRECLOVIR.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call